top of page

We envision a world free of neurodegenerative diseases.

X-tosis is dedicated to revolutionizing the treatment of neurodegenerative diseases, starting with Alzheimer’s and extending to other conditions. Our mission is to develop innovative solutions that target the underlying causes, offering hope to patients and their families.

Background

X-tosis, founded in July 2024, is a biotechnology company dedicated to advancing innovative treatments for neurodegenerative diseases. Our development is based on over two decades of research by Professor Varda Shoshan-Barmatz, a leading scientist in the field of mitochondrial dysfunction and apoptosis. Her pioneering work has laid the foundation for X-tosis’s unique approach to targeting neurodegeneration through the inhibition of the VDAC1 protein, a critical player in cell death mechanisms.
 

At X-tosis, we are driven by a mission to transform the treatment landscape for Alzheimer’s and other neurodegenerative diseases, focusing on mitochondrial health to protect neuronal cells and enhance cell survival. Our novel XTS compounds halts VDAC1 oligomerization, effectively preventing apoptosis triggered by amyloid-beta and other cellular stressors.

Through this approach, X-tosis is at the forefront of developing therapies that aim to mitigate disease progression and improve patients' quality of life.

 

With a team of dedicated scientists, industry experts, and collaborators, X-tosis stands committed to making a lasting impact on the lives of patients worldwide, turning decades of research into transformative healthcare solutions.

Value Proposition

+972-52-5688574

3501 S Main Street, Suite 1
Gainesville, FL 32601

info@x-tosis.com

  • LinkedIn

Contact Us

Thank you for contacting

bottom of page